Efficacy of inhaled nebulised unfractionated heparin to prevent intubation or death in hospitalised patients with COVID-19: an investigator-initiated international meta-trial of randomised clinical studies
Issued Date
2025-10-01
Resource Type
eISSN
25895370
Scopus ID
2-s2.0-105020474704
Journal Title
Eclinicalmedicine
Volume
88
Rights Holder(s)
SCOPUS
Bibliographic Citation
Eclinicalmedicine Vol.88 (2025)
Suggested Citation
van Haren F.M.P., Valle S.J., Neto A.S., Schultz M.J., Laffey J.G., Artigas A., Dixon B., Vilaseca A.B., Barbera R.A., Ismail T.I., Mahrous R.S., Badr M., DeNucci G., Sverdloff C., Camprubi-Rimblas M., Cosgrave D.W., McNicholas B., Cody C., Curley G., Smoot T.L., Staas S., Sann K., Sas C., Belani A., Hillman C., Manggala S.K., Aditianingsih D., Sugiarto A., Yulianti M., Herikurniawan H., Sinto R., Auerkari A.N., Permana S.A., Woodcock A., Carroll M., Wilkinson T., Singh D., Shute J.K., Carroll M., Page C. Efficacy of inhaled nebulised unfractionated heparin to prevent intubation or death in hospitalised patients with COVID-19: an investigator-initiated international meta-trial of randomised clinical studies. Eclinicalmedicine Vol.88 (2025). doi:10.1016/j.eclinm.2025.103339 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112954
Title
Efficacy of inhaled nebulised unfractionated heparin to prevent intubation or death in hospitalised patients with COVID-19: an investigator-initiated international meta-trial of randomised clinical studies
Author(s)
van Haren F.M.P.
Valle S.J.
Neto A.S.
Schultz M.J.
Laffey J.G.
Artigas A.
Dixon B.
Vilaseca A.B.
Barbera R.A.
Ismail T.I.
Mahrous R.S.
Badr M.
DeNucci G.
Sverdloff C.
Camprubi-Rimblas M.
Cosgrave D.W.
McNicholas B.
Cody C.
Curley G.
Smoot T.L.
Staas S.
Sann K.
Sas C.
Belani A.
Hillman C.
Manggala S.K.
Aditianingsih D.
Sugiarto A.
Yulianti M.
Herikurniawan H.
Sinto R.
Auerkari A.N.
Permana S.A.
Woodcock A.
Carroll M.
Wilkinson T.
Singh D.
Shute J.K.
Carroll M.
Page C.
Valle S.J.
Neto A.S.
Schultz M.J.
Laffey J.G.
Artigas A.
Dixon B.
Vilaseca A.B.
Barbera R.A.
Ismail T.I.
Mahrous R.S.
Badr M.
DeNucci G.
Sverdloff C.
Camprubi-Rimblas M.
Cosgrave D.W.
McNicholas B.
Cody C.
Curley G.
Smoot T.L.
Staas S.
Sann K.
Sas C.
Belani A.
Hillman C.
Manggala S.K.
Aditianingsih D.
Sugiarto A.
Yulianti M.
Herikurniawan H.
Sinto R.
Auerkari A.N.
Permana S.A.
Woodcock A.
Carroll M.
Wilkinson T.
Singh D.
Shute J.K.
Carroll M.
Page C.
Author's Affiliation
Universidade de São Paulo
The University of Manchester
Monash University
University of Southampton
Universidade Estadual de Campinas
Faculty of Life Sciences & Medicine
Universitas Indonesia
University of Galway
University of Portsmouth
Nuffield Department of Medicine
St. Vincent's Hospital Melbourne
Beaumont Hospital
Faculty of Medicine
Austin Hospital
St George Hospital
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
University Hospital Galway
Mahidol Oxford Tropical Medicine Research Unit
ANU College of Health & Medicine
Institut d’Investigació i Innovació Parc Taulí (I3PT)
Faculty of Medicine
Amsterdam UMC
Frederick Memorial Hospital
Clínica San Camilo
RSUD Dr. Moewardi
Connolly Memorial Hospital Blanchardstown
ACTGen
The University of Manchester
Monash University
University of Southampton
Universidade Estadual de Campinas
Faculty of Life Sciences & Medicine
Universitas Indonesia
University of Galway
University of Portsmouth
Nuffield Department of Medicine
St. Vincent's Hospital Melbourne
Beaumont Hospital
Faculty of Medicine
Austin Hospital
St George Hospital
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
University Hospital Galway
Mahidol Oxford Tropical Medicine Research Unit
ANU College of Health & Medicine
Institut d’Investigació i Innovació Parc Taulí (I3PT)
Faculty of Medicine
Amsterdam UMC
Frederick Memorial Hospital
Clínica San Camilo
RSUD Dr. Moewardi
Connolly Memorial Hospital Blanchardstown
ACTGen
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Inhaled nebulised unfractionated heparin (UFH) has a strong rationale as a treatment for severe respiratory infections, including COVID-19, due to its antiviral, anti-inflammatory, and anti-coagulant properties, which may prevent viral entry, lung injury progression, and pulmonary thrombosis. We aimed to evaluate the efficacy of inhaled nebulised UFH to prevent intubation or death in hospitalised COVID-19 patients. Methods: In this prospective, a priori set up and defined, collaborative meta-trial of six randomised clinical studies, adult hospitalised but not intubated COVID-19 patients were randomly assigned to inhaled nebulised UFH on top of standard of care or standard of care alone. The dose and method of nebulisation was specific to each study. The primary outcome was intubation or death, assessed at the longest follow-up after randomisation. The meta-trial was registered atClinicalTrials.govIDNCT04635241. Findings: Between June 2020 and December 2022, 478 patients from 10 hospitals in six countries (Argentina, Brazil, Egypt, Indonesia, Ireland and USA) were enrolled. The odds ratio (OR) for intubation or death was 0.43 (0.26–0.73, p = 0.001); the OR for in-hospital mortality was 0.26 (0.13–0.54, p < 0.001) with inhaled nebulised UFH compared to standard of care alone. There were no safety issues reported, including no instances of pulmonary or systemic bleeding in the nebulised UFH group. Interpretation: In patients hospitalised but not intubated for COVID-19, inhaled nebulised UFH prevented intubation and reduced mortality, without causing pulmonary or systemic bleeding. Funding: The Sponsor of the meta-trial was the INHALE-HEP Collaborative Research Group (CRG); investigators of each contributing study were members of the INHALE-HEP CRG. No funding was received for the meta-trial. The Brazilian study was funded by The J.R. Moulton Charity Trust. The Irish study was funded by a Grant from Science Foundation Ireland to Cúram, the SFI's Centre for Research in Medical Devices (Research Centre Award Reference:13/RC/2073).